Document is current
Any future updates will be listed below
-
Authors
Senapedis, William https://orcid.org/0009-0004-1566-2733
Gallagher, Kayleigh M.
Figueroa, Elmer https://orcid.org/0009-0005-0772-9632
Farelli, Jeremiah D. https://orcid.org/0000-0003-2742-2257
Lyng, Robert
Hodgson, J. Graeme
O’Donnell, Charles W.
Newman, Joseph V.
Pacaro, Madison https://orcid.org/0000-0002-1443-020X
Siecinski, Stephen K.
Chen, Justin https://orcid.org/0000-0002-1661-4547
McCauley, Thomas G. https://orcid.org/0009-0002-6261-9119
- License Information
-
More Information
Article History
Received: 26 September 2023
Accepted: 29 August 2024
First Online: 16 September 2024
Competing interests
: All authors were employees of Omega Therapeutics when the work was conducted. All authors were or currently are shareholders of Omega Therapeutics stock and/or options. T.G.M. is the Chief Scientific Officer of Omega Therapeutics.
